|
ZNF766 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.91100005106659E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.18409999583236E-08 |
| Normal-vs-Stage2 |
2.85689999990346E-07 |
| Normal-vs-Stage3 |
2.89399999520157E-08 |
| Normal-vs-Stage4 |
7.23430204629949E-11 |
| Stage1-vs-Stage2 |
9.461400E-01 |
| Stage1-vs-Stage3 |
9.666400E-01 |
| Stage1-vs-Stage4 |
1.148050E-02 |
| Stage2-vs-Stage3 |
9.726600E-01 |
| Stage2-vs-Stage4 |
9.596300E-02 |
| Stage3-vs-Stage4 |
3.243800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.16730000110365E-08 |
| Normal-vs-AfricanAmerican |
4.26740000003534E-06 |
| Normal-vs-Asian |
2.52360000008167E-07 |
| Caucasian-vs-AfricanAmerican |
9.212800E-01 |
| Caucasian-vs-Asian |
8.875600E-01 |
| AfricanAmerican-vs-Asian |
9.949200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.23749999639367E-08 |
| Normal-vs-Female |
4.42600001093751E-09 |
| Male-vs-Female |
7.586600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.52460000180099E-08 |
| Normal-vs-Age(41-60Yrs) |
1.60849999986112E-08 |
| Normal-vs-Age(61-80Yrs) |
3.72590003294704E-09 |
| Normal-vs-Age(81-100Yrs) |
2.598200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.471600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.503200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.992800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.162600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.203600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.499000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.226380E-01 |
| Classical-VS-Follicular |
1.587650E-04 |
| Classical-VS-Other |
4.145200E-01 |
| Classical-VS-Normal |
2.33279999983793E-07 |
| Tall-VS-Follicular |
3.092400E-01 |
| Tall-VS-Other |
7.462000E-01 |
| Tall-VS-Normal |
2.45669999898723E-08 |
| Follicular-VS-Other |
9.988400E-01 |
| Follicular-VS-Normal |
2.07399986074108E-10 |
| Other-VS-Normal |
4.821200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.25089996325801E-09 |
| Normal-vs-N1 |
2.12119988241E-10 |
| N0-vs-N1 |
3.666000E-02 |
|
|
